Salvage therapy with intravenous fosfomycin plus ceftriaxone for necrotizing fasciitis caused by penicillin-nonsusceptible Streptococcus pneumoniae

Zhang, Chun Cheng; Weng, Tzu Chieh; Su, Bo; Lai, Chih Cheng; Chuang, Yin Ching; Ko, Wen Chien; Tang, Hung Jen

doi:10.1016/j.jmii.2016.08.005

Cited by 5 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a letter to the editor one group described their experience with fosfomycin and ceftriaxone to treat a patient with diabetes and penicillin‐nonsusceptible S. pneumoniae necrotizing fasciitis. This combination, along with extensive surgical debridement, yielded favorable results.…”

Section: Clinical Efficacy Datamentioning

confidence: 99%

Parenteral Fosfomycin for the Treatment of Multidrug Resistant Bacterial Infections: The Rise of the Epoxide

2019

View full text Add to dashboard Cite

Fosfomycin was initially discovered in 1969 but has recently gained renewed interest for the treatment of multidrug‐resistant (MDR) bacterial infections, particularly in the United States. Its unique mechanism of action, bactericidal activity, broad spectrum of activity, and relatively safe and tolerable adverse effect profile make it a great addition to the dwindling antibiotic armamentarium. Fosfomycin contains a three‐membered epoxide ring with a direct carbon to phosphorous bond that bypasses the intermediate oxygen bond commonly present in other organophosphorous compounds; this structure makes the agent unique from other antibiotics. Despite nearly 50 years of parenteral fosfomycin use in Europe, fosfomycin has retained stable activity against most pathogens. Furthermore, fosfomycin demonstrated in vitro synergy in combination with other cell wall–active antibiotics (e.g., β‐lactams, daptomycin). These combinations may offer respite for severe infections due to MDR gram‐positive and gram‐negative bacteria. The intravenous (IV) formulation is currently under review in the United States, and apropos, this review collates more contemporary evidence (i.e., studies published between 2000 and early 2019) in anticipation of this development. The approval of IV fosfomycin provides another option for consideration in the management of MDR infections. Its unique structure will give rise to a promising epoxide epoch in the battle against MDR bacteria.

show abstract

Section: Clinical Efficacy Datamentioning

confidence: 99%